Video
Dr. Dumoulin on NVALT 12 Data in NSCLC
Author(s):
Daphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.
Daphne Dumoulin, MD, pulmonologist, Erasmus MC Cancer Institute, Netherlands, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non—small cell lung cancer (NSCLC).
After treating patients with 6 weeks of paclitaxel/carboplatin/bevacizumab, there was an increase in the number of proliferating CD8 T cells compared with baseline. Meanwhile, CD4 T cells remained stable. Proliferating CD8 T cells express PD-1 more frequently and express more PD-1 per cell compared with non-proliferating CD8 T cells, according to Dumoulin. However, patients with more than a two-fold increase in proliferation of T cells did not show a better outcome.
The study shows paclitaxel/carboplatin/bevacizumab induces proliferation of CD8 T cells and expresses more co-inhibitory checkpoint molecules. The next step, according to Dumoulin, is to investigate if these proliferating CD8+ T cells are predictive of a response to checkpoint inhibition therapy as sequential or concurrent therapy.
